X
[{"orgOrder":0,"company":"Synthonics","sponsor":"RS BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.A.E","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Synthonics","sponsor":"RS BioTherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.A.E","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Synthonics","sponsor":"RS BioTherapeutics","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Secures $3 Million Seed II Round of Funding","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.A.E","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Synthonics
Filters
Companies By Therapeutic Area
Details:
RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases.
Lead Product(s):
Cannabidiolic Acid Complex
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: RSBT-001
Highest Development Status: Preclinical
Product Type: Small molecule
Recipient:
RS BioTherapeutics
Deal Size: $3.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
September 26, 2022
Details:
The data from the proof-of-concept trial clearly indicates that RSBT-001, is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid (CBDa) reduces cytokine level, and that this cytokine reduction is appropriately transient.
Lead Product(s):
RSBT-001
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: RSBT-001
Highest Development Status: Preclinical
Product Type: Small molecule
Recipient:
RS BioTherapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 11, 2022
Details:
Under the license agreement with Synthonics, Inc. for the exclusive, worldwide right for RS BioTherapeutic's lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD).
Lead Product(s):
RSBT-001
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: RSBT-001
Highest Development Status: Preclinical
Product Type: Small molecule
Recipient:
RS BioTherapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
May 23, 2022